Skip to content
Screener

Castle Biosciences CSTL Q3 2025 earnings

Reported November 3, 2025 · After market close

Revenue$83.0MBeat by $2.7M
EPS-$0.02Beat by $0.32
Revenue estimate$80.4M
EPS estimate-$0.34

Next report

Nov 2, 2026 (in a month)
Revenue estimate$92.1M
EPS estimate-$0.38

Financials

Q3 2025

Income statement

See full
Revenue$83.0M-3.2%
Gross profit$64.3M-8.3%
Operating income-$6.8M-234%
Net income-$501.0K-122%
EPS (diluted)-$0.02-125%

Balance sheet

See full
Cash & equivalents$85.6M-9.9%
Total debt$37.1M+38.9%
Total equity$467.0M+5.9%
Total assets$562.8M+9.4%

Cash flow

See full
Operating cash flow$22.6M-3.0%
CapEx$14.8M+133%
Free cash flow$7.8M-54.0%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$660.52M-16.5%
Enterprise value$612.1M-15.3%
P/S1.9×-0.6×

Profitability

See full
Gross margin79.9%-2.0pp
Operating margin-10.2%-10.5pp
Net margin-3.6%-5.5pp
FCF margin7.4%—

Returns & leverage

See full
Return on equity-2.7%-4.2pp
Debt / equity0.1×0.0×
Current ratio6.5×-1.3×

Segments

By product

See full
Dermatologic$48.5M-25.4%
Non-Dermatologic$34.5M+66.6%

By segment

See full
Reportable Segment$83.0M-3.2%

FAQ

When did Castle Biosciences report Q3 2025 earnings?
Castle Biosciences (CSTL) reported Q3 2025 earnings on November 3, 2025 after market close.
What were Castle Biosciences's Q3 2025 revenue and EPS?
Castle Biosciences reported revenue of $83.0M and eps of $-0.02 for Q3 2025.
Did Castle Biosciences beat estimates in Q3 2025?
Revenue beat the consensus estimate of $80.4M by $2.7M. EPS beat the consensus estimate of $-0.34 by $0.32.
How did Castle Biosciences's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 3.2% from $85.8M a year earlier.
Where can I find Castle Biosciences's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-048248) and the 10-Q periodic report (0001628280-25-048254) directly on SEC EDGAR. The filing index links above go to sec.gov.